BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis

NASDAQ:BMRN • US09061G1013

59.95 USD
+0.08 (+0.13%)
At close: Feb 17, 2026
59.95 USD
0 (0%)
After Hours: 2/17/2026, 5:07:13 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to BMRN. BMRN was compared to 521 industry peers in the Biotechnology industry. BMRN gets an excellent profitability rating and is at the same time showing great financial health properties. A decent growth rate in combination with a cheap valuation! Better keep an eye on BMRN. These ratings would make BMRN suitable for value and quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year BMRN was profitable.
  • In the past year BMRN had a positive cash flow from operations.
  • Of the past 5 years BMRN 4 years were profitable.
  • In the past 5 years BMRN always reported a positive cash flow from operatings.
BMRN Yearly Net Income VS EBIT VS OCF VS FCFBMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

  • The Return On Assets of BMRN (6.83%) is better than 92.51% of its industry peers.
  • BMRN has a better Return On Equity (8.59%) than 91.94% of its industry peers.
  • The Return On Invested Capital of BMRN (7.69%) is better than 93.67% of its industry peers.
  • BMRN had an Average Return On Invested Capital over the past 3 years of 3.73%. This is significantly below the industry average of 18.54%.
  • The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(7.69%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROIC 7.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
BMRN Yearly ROA, ROE, ROICBMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

  • BMRN's Profit Margin of 16.82% is amongst the best of the industry. BMRN outperforms 92.51% of its industry peers.
  • BMRN has a better Operating Margin (20.21%) than 94.43% of its industry peers.
  • The Gross Margin of BMRN (81.32%) is better than 85.41% of its industry peers.
  • BMRN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
BMRN Yearly Profit, Operating, Gross MarginsBMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BMRN is destroying value.
  • Compared to 1 year ago, BMRN has more shares outstanding
  • The number of shares outstanding for BMRN has been increased compared to 5 years ago.
  • BMRN has a better debt/assets ratio than last year.
BMRN Yearly Shares OutstandingBMRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BMRN Yearly Total Debt VS Total AssetsBMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • BMRN has an Altman-Z score of 5.62. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.62, BMRN is in the better half of the industry, outperforming 73.90% of the companies in the same industry.
  • The Debt to FCF ratio of BMRN is 0.72, which is an excellent value as it means it would take BMRN, only 0.72 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.72, BMRN belongs to the best of the industry, outperforming 94.24% of the companies in the same industry.
  • A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
  • BMRN has a worse Debt to Equity ratio (0.10) than 62.00% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Altman-Z 5.62
ROIC/WACC0.93
WACC8.25%
BMRN Yearly LT Debt VS Equity VS FCFBMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • A Current Ratio of 4.83 indicates that BMRN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.83, BMRN is in line with its industry, outperforming 55.28% of the companies in the same industry.
  • BMRN has a Quick Ratio of 3.10. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
  • BMRN has a Quick ratio of 3.10. This is in the lower half of the industry: BMRN underperforms 61.04% of its industry peers.
Industry RankSector Rank
Current Ratio 4.83
Quick Ratio 3.1
BMRN Yearly Current Assets VS Current LiabilitesBMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 52.00% over the past year.
  • BMRN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.39%.
  • Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.86% on average per year.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.59% on average over the next years. This is a very strong growth
  • BMRN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.09% yearly.
EPS Next Y22.03%
EPS Next 2Y41.64%
EPS Next 3Y34.83%
EPS Next 5Y22.59%
Revenue Next Year12.66%
Revenue Next 2Y11.16%
Revenue Next 3Y10.76%
Revenue Next 5Y8.09%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BMRN Yearly Revenue VS EstimatesBMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
BMRN Yearly EPS VS EstimatesBMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 22.54, BMRN is valued on the expensive side.
  • Based on the Price/Earnings ratio, BMRN is valued cheaply inside the industry as 94.63% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.19, BMRN is valued at the same level.
  • The Price/Forward Earnings ratio is 13.52, which indicates a correct valuation of BMRN.
  • Based on the Price/Forward Earnings ratio, BMRN is valued cheaper than 96.74% of the companies in the same industry.
  • BMRN is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 22.54
Fwd PE 13.52
BMRN Price Earnings VS Forward Price EarningsBMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMRN is cheaper than 95.39% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BMRN is valued cheaply inside the industry as 97.12% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.95
EV/EBITDA 14.68
BMRN Per share dataBMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of BMRN may justify a higher PE ratio.
  • BMRN's earnings are expected to grow with 34.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.02
PEG (5Y)N/A
EPS Next 2Y41.64%
EPS Next 3Y34.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (2/17/2026, 5:07:13 PM)

After market: 59.95 0 (0%)

59.95

+0.08 (+0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27
Earnings (Next)02-25
Inst Owners97.82%
Inst Owner Change0.78%
Ins Owners0.64%
Ins Owner Change-0.95%
Market Cap11.52B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.25
Price Target94.32 (57.33%)
Short Float %4.15%
Short Ratio3.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)2.44%
PT rev (3m)-1.45%
EPS NQ rev (1m)-36.59%
EPS NQ rev (3m)-35.34%
EPS NY rev (1m)-10.07%
EPS NY rev (3m)-11.2%
Revenue NQ rev (1m)0.45%
Revenue NQ rev (3m)0.28%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)0.19%
Valuation
Industry RankSector Rank
PE 22.54
Fwd PE 13.52
P/S 3.72
P/FCF 13.95
P/OCF 12.6
P/B 1.9
P/tB 2.05
EV/EBITDA 14.68
EPS(TTM)2.66
EY4.44%
EPS(NY)4.43
Fwd EY7.4%
FCF(TTM)4.3
FCFY7.17%
OCF(TTM)4.76
OCFY7.94%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)1.02
PEG (5Y)N/A
Graham Number43.44
Profitability
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROCE 9.17%
ROIC 7.69%
ROICexc 9.82%
ROICexgc 10.68%
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
FCFM 26.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Debt/EBITDA 0.84
Cap/Depr 106.6%
Cap/Sales 2.85%
Interest Coverage 85.91
Cash Conversion 129.08%
Profit Quality 158.68%
Current Ratio 4.83
Quick Ratio 3.1
Altman-Z 5.62
F-Score8
WACC8.25%
ROIC/WACC0.93
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y22.03%
EPS Next 2Y41.64%
EPS Next 3Y34.83%
EPS Next 5Y22.59%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.66%
Revenue Next 2Y11.16%
Revenue Next 3Y10.76%
Revenue Next 5Y8.09%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.1%
EBIT Next 3Y41.17%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%

BIOMARIN PHARMACEUTICAL INC / BMRN FAQ

Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?

ChartMill assigns a fundamental rating of 6 / 10 to BMRN.


What is the valuation status for BMRN stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.


Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?

BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.


What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?

The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.


What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?

The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 22.03% in the next year.